22 février 2023
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.53738/REVMED.2023.19.815.354
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/36815324
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_469DBB5891AC9
info:eu-repo/semantics/embargoedAccess , Restricted: cannot be viewed until 2024-08-22 , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
M. Ballester et al., « Le point sur l’asthme en pédiatrie : optimisation de la prise en charge et thérapies biologiques [Where we stand with asthma: optimized medical care and biologic therapy for children] », Serveur académique Lausannois, ID : 10.53738/REVMED.2023.19.815.354
Asthma recommendations are in constant evolution. Salbutamol exclusivity as the historical reference treatment for asthma exacerbations is now questioned. In case of light to moderate crisis, budesonide/formoterol, combining an inhaled corticosteroid and a fast acting long lasting beta2 agonist, can now be proposed as first line as needed treatment, for adolescents older than 12 years old. In addition, progress in fundamental research revealed the heterogeneous nature of asthma and allowed for the emergence of new-targeted therapies.